SPECTRUM PHARMACEUTICALS, INC. (NASDAQ:SPPI) Files An 8-K Other Events
Item 8.01Other Events.
On December 19, 2018, Spectrum Pharmaceuticals, Inc. issued a press release announcing that, based on a subset of data from MD Anderson’s ongoing Phase 2 study, the U.S. Food and Drug Administration (FDA) did not grant Breakthrough Therapy Designation (BTD) to poziotinib for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 20 mutations. A copy of such press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit No. |
Description |
|
99.1 |
Press Release dated December 19, 2018
|
SPECTRUM PHARMACEUTICALS INC Exhibit
EX-99.1 2 exhibit9912018-12×19.htm EXHIBIT 99.1 Exhibit COMPANY CONTACTShiv KapoorVice President,…
To view the full exhibit click here
About SPECTRUM PHARMACEUTICALS, INC. (NASDAQ:SPPI)
Spectrum Pharmaceuticals, Inc. is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has approximately six approved oncology/hematology products that target different types of non-Hodgkin’s lymphoma (NHL), metastatic colorectal cancer, acute lymphoblastic leukemia (ALL) and multiple myeloma (MM). It also has two drugs in late-stage development: SPI-2012, which is being developed for chemotherapy-induced neutropenia in patients with breast cancer, and EOQUIN, which is being developed for immediate intravesical instillation post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer. It has a product portfolio consisting of both commercial-stage and development-stage products that address various cancer types. Its commercialized products include FUSILEV, FOLOTYN, ZEVALIN, MARQIBO, BELEODAQ and EVOMELA. Its other products include SPI-2012, POZIOTINIB and EOQUIN.